University of Louisville

About: University of Louisville is a education organization based out in Louisville, Kentucky, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 24600 authors who have published 49248 publications receiving 1573346 citations. The organization is also known as: UofL.

Curiosity and pathways to well-being and meaning in life: Traits, states, and everyday behaviors

Abstract: This study examined curiosity as a mechanism for achieving and maintaining high levels of well-being and meaning in life. Of primary interest was whether people high in trait curiosity derive greater well-being on days when they are more curious. We also tested whether trait and daily curiosity led to greater, sustainable well- being. Predictions were tested using trait measures and 21 daily diary reports from 97 college students. We found that on days when they are more curious, people high in trait curiosity reported more frequent growth-oriented behav- iors, and greater presence of meaning, search for meaning, and life satisfaction. Greater trait curiosity and greater curiosity on a given day also predicted greater persistence of meaning in life from one day into the next. People with greater trait curiosity reported more frequent hedonistic events but they were associated with less pleasure com- pared to the experiences of people with less trait curiosity. The benefits of hedonistic events did not last beyond the day of their occurrence. As evidence of construct speci- ficity, curiosity effects were not attributable to Big Five personality traits or daily positive or negative mood. Our results provide support for curiosity as an ingredient in the development of well-being and meaning in life. The pattern of findings casts doubt on some distinctions drawn between eudaimonia and hedonic well-being traditions.

Characterization of human chorionic gonadotropin as a novel angiogenic factor.

Abstract: Angiogenesis and vascular remodeling are crucial processes in tumor invasion and metastasis as well as in embryo implantation and normal development of the placenta. We have previously shown that hCG expressed in trophoblast and various malignant tumors promotes cellular motility and that uterine endothelium expresses hCG/LH receptor in vivo. In this study hCG was proposed to promote angiogenesis. A three-dimensional in vitro angiogenesis system consisting of uterine microvascular endothelial cells seeded on microcarriers and entrapped in a fibrin matrix was used to study the influence of hCG on neovascularization. Physiological concentrations of hCG (5-50,000 mU/ml) significantly increased in vitro capillary formation (up to 2.5-fold) and migration of endothelial cells in a Boyden chamber assay (up to 3.6-fold) in a dose-dependent manner, whereas hCG had no effect on cell proliferation. In vivo, hCG induced neovascularization in the chicken chorioallantoic membrane assay comparable to the activity of vascular endothelial growth factor. hCG-secreting tumors (choriocarcinoma, endometrium, and ovarian carcinoma) promoted in vitro neovascularization (up to 3-fold), whereas hCG-neutralizing antibody, pertussis toxin (G protein inhibitor), or GRGDTP peptide (integrin antagonist), respectively, abolished both tumor- and hCG-induced capillary sprout formation. Our data indicate a novel function for hCG in uterine adaptation to early pregnancy as well as in tumor development and underline the importance of hCG as an as yet unrecognized angiogenic factor.

HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial.

Abstract: Background The HeartWare Ventricular Assist System (HeartWare Inc, Framingmam, MA) is a miniaturized implantable, centrifugal design, continuous-flow blood pump. The pivotal bridge to transplant and continued access protocols trials have enrolled patients with advanced heart failure in a bridge-to-transplant indication. Methods The primary outcome, success, was defined as survival on the originally implanted device, transplant, or explant for ventricular recovery at 180 days. Secondary outcomes included an evaluation of survival, functional and quality of life outcomes, and adverse events. Results A total of 332 patients in the pivotal bridge to transplant and continued access protocols trial have completed their 180-day primary end-point assessment. Survival in patients receiving the HeartWare pump was 91% at 180 days and 84% at 360 days. Quality of life scores improved significantly, and adverse event rates remain low. Conclusions The use of the HeartWare pump as a bridge to transplant continues to demonstrate a high 180-day survival rate despite a low rate of transplant. Adverse event rates are similar or better than those observed in historical bridge-to-transplant trials, despite longer exposure times due to longer survival and lower transplant rates.